−2.9773USD
−12.51 MUSD
23.95 M
About Kiora Pharmaceuticals, Inc.
Sector
CEO
Brian Matthew Strem
Headquarters
Encinitas
Website
Employees (FY)
12
Founded
1998
FIGI
BBG0083Y1PH9
Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of KPRX is 0.4850 USD — it has decreased by 1.08% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Kiora Pharmaceuticals, Inc. stocks are traded under the ticker KPRX.
Kiora Pharmaceuticals, Inc. is going to release the next earnings report on May 15, 2024. Keep track of upcoming events with our Earnings Calendar.
KPRX stock is 9.18% volatile and has beta coefficient of 0.07. Check out the list of the most volatile stocks — is Kiora Pharmaceuticals, Inc. there?
One year price forecast for Kiora Pharmaceuticals, Inc. has a max estimate of 6.0000 USD and a min estimate of 2.0000 USD.
KPRX earnings for the last quarter are −0.89 USD per share, whereas the estimation was −0.52 USD resulting in a −71.15% surprise. The estimated earnings for the next quarter are −0.39 USD per share. See more details about Kiora Pharmaceuticals, Inc. earnings.
Yes, you can track Kiora Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
KPRX stock has fallen by 15.65% compared to the previous week, the month change is a 18.84% fall, over the last year Kiora Pharmaceuticals, Inc. has showed a 86.41% decrease.
KPRX net income for the last quarter is −2.27 M USD, while the quarter before that showed −5.76 M USD of net income which accounts for 60.63% change. Track more Kiora Pharmaceuticals, Inc. financial stats to get the full picture.
Today Kiora Pharmaceuticals, Inc. has the market capitalization of 12.87 M, it has increased by 0.75% over the last week.
No, KPRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, KPRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kiora Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 12.00 employees. See our rating of the largest employees — is Kiora Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kiora Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kiora Pharmaceuticals, Inc. stock shows the sell signal. See more of Kiora Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Kiora Pharmaceuticals, Inc. future price: according to them, KPRX price has a max estimate of 6.00 USD and a min estimate of 2.00 USD. Read a more detailed Kiora Pharmaceuticals, Inc. forecast: see what analysts think of Kiora Pharmaceuticals, Inc. and suggest that you do with its stocks.